Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

NCT02127801 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: REGN1908-1909
DRUG: placebo

Sponsor

Regeneron Pharmaceuticals